1 most recent filing and news item mentioning QNCX. Updated every 60 seconds.
M&A|OfferingAug 17, 2026Neutral
Quince Therapeutics acquired Orphai Therapeutics for an aggregate of 67,101 Shares of Series C Preferred Stock and concurrently raised approximately $115 million through a PIPE offering to fund the acquisition.
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.